

## Supplemental materials

### Materials and methods

#### Protein expression and purification

INTAC was overexpressed and purified as previously described ([Zheng et al., 2020](#)). INTAC containing the catalytic mutant INTS11 (E203Q) was purified with minor modifications. For INTAC (E203Q), only INTS11 was tagged with an N-terminal 4×Protein A to avoid the contamination of endogenous INTS11. Pol II was isolated from *S. scrofa* thymus and purified following the reported protocol ([Chen et al., 2021](#)). Four residue substitutions (G882S of RBP2, T75I of RPB3, S140N of RPB3, and S126T of RPB6) exist between *S. scrofa* and *H. sapiens* Pol II.

All the purification steps were performed at 4 °C unless otherwise stated. The two full-length open reading frames (ORFs) of human DSIF subunits (SPT4 and SPT5) were separately subcloned into a modified pCAG vector and SPT4 was tagged with an N-terminal 2 × Protein A. Both plasmids were co-transfected to Expi293F cells using PEI (Polysciences) when the cells reached a density of  $2.5 \times 10^6$ /ml. After being cultured at 37 °C for 60 hours, cells were harvested and lysed in lysis buffer containing 50 mM Na-HEPES pH 7.4, 300 mM NaCl, 0.25% CHAPS, 5 mM MgCl<sub>2</sub>, 5 mM adenosine triphosphate (ATP), 10% glycerol (v/v), 2 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml aprotinin, 1 µg/ml pepstatin, 1 µg/ml leupeptin for 30 min. The lysate was clarified by centrifugation at 16,000 rotations per minute (rpm) for 30 min with JLA-16.250 rotor (Beckman Coulter), and the supernatant was incubated with immunoglobulin G (IgG) resins (Smart-Lifesciences) overnight. The resins were washed with buffer containing 30 mM Na-HEPES pH 7.4, 300 mM NaCl, 0.1% CHAPS, 2 mM MgCl<sub>2</sub>, 10% glycerol, 2 mM DTT. After on-column cleavage by 3C protease for 4 hours, the immobilized proteins were eluted and further purified by ion exchange chromatography (Mono Q 5/5, GE Healthcare). Peak fractions were assessed by SDS-PAGE followed by Coomassie blue staining. Protein concentration was determined by measuring absorption at 280 nm and using the predicted extinction coefficient for DSIF. Pure fractions were pooled, aliquoted, snap frozen and stored at -80 °C.

NELF was prepared essentially in a similar way as described in DSIF. The four full-length ORFs of human NELF subunits (NELF-A, -B, -C, -E) were separately subcloned into a modified pCAG vector and NELF-E was tagged with an N-terminal 2 × Protein A. The plasmids were co-transfected into Expi293F cells for overexpression. The cells were collected by centrifugation and resuspended in lysis buffer containing 50 mM Na-HEPES pH 7.4, 300 mM NaCl, 0.25% CHAPS, 5 mM MgCl<sub>2</sub>, 5 mM ATP, 10% glycerol (v/v), 2 mM DTT, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml pepstatin, 1 µg/ml leupeptin. After cell lysis, the lysate was cleared by centrifugation and the supernatant was incubated with IgG resins (Smart-Lifesciences) for 4 hours followed by on-column digestion by 3C protease for 4 hours. The

38 eluate was further purified by ion exchange chromatography (Mono Q 5/5, GE Healthcare).  
39 Peak fractions were pooled and protein purity was assessed by SDS–PAGE and Coomassie  
40 staining. Pure NELF was concentrated and subjected to in vitro dephosphorylation overnight  
41 by Lambda Protein Phosphatase (Lambda PP, Beyotime Biotechnology). The dephosphorylated  
42 NELF was applied onto a Superdex200 10/300 GL column (GE Healthcare) in a buffer  
43 containing 30 mM K-HEPES pH 7.4, 150 mM KCl, 5% glycerol (v/v), 2 mM DTT. Peak  
44 fractions containing NELF were pooled, aliquoted, snap frozen, and stored at –80 °C.

45

#### 46 **Cryo-EM sample preparation**

47 DNA oligos were purchased from Generay Biotechnology and RNA oligos were  
48 purchased from Bioneer. All oligos were resuspended in RNase-free water (200 µM) and stored  
49 at –30 °C. The Pol II elongation complex (EC) was assembled on a bubble scaffold with the  
50 following nucleic acid sequences as previously reported with minor modifications ([Vos et al.,](#)  
51 [2018a](#)): template DNA 5'-GCT CCC AGC TCC CTG CTG GCT CCG AGT GGG TTC CGC  
52 CGC TCT CAA TGG-3', non-template DNA 5'-CCA TTG AGA GCG GCA CTT GTG TTC  
53 CGG AGC CAG CAG GGA GCT GGG AGC-3', and RNA 5'-Phosphorylation-AAU AAC  
54 CGG AGA GGG AAC CCA CU-3'. The scaffold contains 10 bp DNA-RNA hybrid, 10-  
55 nucleotide bubble, 13 nucleotides of exit RNA, 24 nucleotides of entry DNA and 14 nucleotides  
56 of exit DNA. To obtain the DNA-RNA hybrid, template DNA and RNA were mixed with a  
57 molar ratio of 1:1.3 and were annealed by incubating the nucleic acids at 95 °C for 10 min and  
58 then decreasing the temperature by 1 °C min<sup>-1</sup> steps to a final temperature of 4 °C in a  
59 thermocycler in a buffer containing 20 mM K-HEPES pH 7.4, 60 mM KCl, 3 mM MgCl<sub>2</sub>, and  
60 5% (v/v) glycerol. All concentrations refer to the final concentrations used in complex assembly.  
61 To assemble EC, the purified *S. scrofa* Pol II (275 pmol) was incubated with twofold molar  
62 excess of the DNA-RNA hybrid for 15 min at 30 °C, shaking at 300 rpm, followed by the  
63 addition of twofold molar excess of non-template DNA and further incubation for 15 min at  
64 30 °C. The purified DSIF and NELF were added in a twofold molar excess relative to Pol II for  
65 the PEC reconstitution. The sample was incubated for 1 hour at 4 °C, followed by the addition  
66 of the purified INTAC (230 pmol) and incubation for another 2 hours at 4 °C. The resulting  
67 sample was subjected to gradient fixation (GraFix) ([Kastner et al., 2008](#)). The glycerol gradient  
68 was prepared using light buffer containing 8% (v/v) glycerol, 20 mM K-HEPES pH 7.4, 60 mM  
69 KCl, 0.03% CHAPS, 2 3mM MgCl<sub>2</sub>, mM DTT, and heavy buffer containing 40% (v/v) glycerol,  
70 0.0018% glutaraldehyde (Sigma), 20 mM HEPES pH 7.4, 60 mM KCl, 0.03% CHAPS, 3mM  
71 MgCl<sub>2</sub>, 2 mM DTT. The centrifugation was performed using an SW60 Ti rotor (Beckman  
72 Coulter) at 32,000 rpm at 4°C for 14 hours. Subsequently, peak fractions were pooled and the  
73 cross-linking reactions were quenched with 100 mM Tris-HCl pH7.0. The homogeneity of peak  
74 fractions was assessed by negative-stain electron microscopy. Fractions of interest were  
75 concentrated to about 1.7 mg/ml and dialyzed overnight against a buffer containing 20 mM K-

76 HEPES pH 7.4, 60 mM KCl, 0.8% glycerol, 1 mM tris (2-carboxyethyl) phosphine (TCEP),  
77 followed by cryo-EM grid preparation.

78 For negative-stain EM, 5  $\mu$ l of freshly purified protein sample was applied onto a glow-  
79 discharged copper grid supported by a thin layer of carbon film for 1 min before negative  
80 staining by 2% (w/v) uranyl formate at room temperature. The negatively stained grid was  
81 loaded onto a FEI Talos L120C microscope operated at 120 kV, equipped with a Ceta CCD  
82 camera.

83 For cryo-EM grid preparation, 4  $\mu$ l of protein sample (about 0.73 mg/ml) was applied onto  
84 a glow-discharged holey carbon grid (Quantifoil Au, R2/2, 300 mesh). After blotting for 3 s,  
85 the grid was vitrified by plunging it into liquid ethane using a Vitrobot Mark IV (FEI) operated  
86 at 4°C and 100% humidity.

87

### 88 **IgG pulldown assay**

89 Expi293F cells containing overexpressed INTAC complex were pelleted and lysed as  
90 previously described ([Zheng et al., 2020](#)). The supernatant of the cell lysate was incubated with  
91 IgG resins for 2 hours at 4°C. The INTAC complex was immobilized on the resins by N-  
92 terminal 4 $\times$ Protein A–tagged INTS1. The resins were extensively washed and resuspended in  
93 450  $\mu$ l of the binding buffer containing 30 mM K-HEPES pH7.4, 100 mM KCl, 0.1% CHAPS,  
94 3 mM MgCl<sub>2</sub>, 8% glycerol, 2 mM DTT. The purified Pol II or Pol II with deletion of RPB1  
95 CTD (Pol II<sup>CTD</sup>) expressed in Expi293F cells was subjected to removing endogenous RPAP2  
96 by incubating with RPAP2 antibody (Abclonal) on Protein G resins. The resulting Pol II, Pol  
97 II<sup>ACTD</sup>, or their mixture with DSIF and NELF, in the presence or absence of a bubble scaffold  
98 was individually incubated with INTAC-immobilized IgG resins for 2 hours at 4°C. The resins  
99 were extensively washed with the binding buffer, and the bound proteins were subjected to  
100 SDS-PAGE followed by Coomassie blue staining. Other IgG pulldown assays were performed  
101 in a similar approach as described above.

102

### 103 **RNA cleavage assay**

104 To test INTAC-mediated RNA cleavage in the context of PEC, five different single-  
105 stranded RNAs (23-nt, 38-nt, 40-nt, 46-nt and 40-nt\*) were used as substrates. 23, 38, 40, 46-  
106 nt RNA: 5'-U<sub>46</sub>UA AGG A<sub>40</sub>AU<sub>38</sub> UAA GUC GUG CGU CUA<sub>23</sub> AUA ACC GGA GAG GGA  
107 ACC CAC U-3' ([Vos et al., 2018a](#)) (The subscripts represent four different RNA lengths from  
108 the 3' end). 40-nt\* RNA: 5'-CAA UAA ACA AGU UAA CAA CAA CAA UUG CAU GGA  
109 ACC CAC U-3' ([Boreikaite et al., 2022](#)). These RNAs were synthesized with a 5' 6-FAM  
110 fluorescent label by GenScript (Nanjing, China) and Bioneer (South Korea). Pol II EC was first  
111 formed using 400 nM of Pol II, 200 nM of annealed DNA-RNA hybrid and 400 nM non-  
112 template DNA at 30 °C and then transferred on ice. 58 nM or 26 nM (only for 46 nt RNA)  
113 INTAC, and 400 nM of DSIF and NELF were then mixed with Pol II EC on ice. All

114 concentrations above refer to the final concentration used in the assay. All cleavage reactions  
115 were performed in 10  $\mu$ l final volume in a buffer containing 20 mM HEPES pH 7.4, 60 mM  
116 KCl, 3 mM MgCl<sub>2</sub>, 10% (v/v) glycerol, 20 mM EDTA, 2 mM DTT, 1 U/ $\mu$ l RNasin® plus  
117 (Promega). The reactions were incubated at 30 °C for 30 min and stopped by adding 10  $\mu$ l of  
118 2x stop buffer (8 urea, 50 mM EDTA, 1x TBE) and boiling at 70 °C for 3 minutes. 4  $\mu$ l of each  
119 reaction was applied to a denaturing gel (8 M urea, 1x TBE, 20% Bis-Tris acrylamide 19:1 gel).  
120 The gel was run in 0.5 x TBE buffer at 550 V for 100 min. Products were visualized using the  
121 6-FAM label and a Typhoon 9500 FLA Imager (GE Healthcare Life Sciences). The cleavage  
122 activity of INTAC (E203Q) was determined in a similar approach as described above.

123

### 124 **Cryo-EM data collection and image processing**

125 Cryo-EM data were collected on a Titan Krios electron microscope (FEI) operated at 300  
126 kV at the Cryo-EM platform of Fudan University, equipped with a K2 summit direct detector  
127 (Gatan) and a GIF quantum energy filter (Gatan) set to a slit width of 20 eV. Automated data  
128 acquisition was carried out with Serial EM software in the super-resolution mode ([Mastrorarde,  
129 2005](#)) at a nominal magnification 130,000 $\times$ , corresponding to a calibrated pixel size of 1.054  
130  $\text{\AA}$ , and a defocus range from  $-1.5$  to  $-2.5$   $\mu$ m. Each image stack was dose fractionated to 32  
131 frames with a total exposure dose of about 50 e<sup>-</sup>/ $\text{\AA}^2$  and exposure time of 6.72 s. The image  
132 stacks were motion-corrected and dose-weighted using MotionCorr2 ([Zheng et al., 2017](#)). The  
133 contrast transfer function (CTF) parameters were estimated by CTFFIND-4.1 from non-dose  
134 weighted micrographs. About 51,000 particles autopicked from 2000 micrographs were  
135 subjected into two-dimensional (2D) classification in RELION v3.0 ([Scheres, 2012](#)) and ab  
136 initio reconstruction by cryoSPARC v2 ([Punjani et al., 2017](#)). The 3D initial model was low-  
137 passed and used as references for subsequent particle-picking and 3D classification. The  
138 following procedures of image processing were performed using RELION for dose-weighted  
139 micrographs, 1,795,128 particles were autopicked from 19,469 micrographs for further data  
140 processing. After several rounds of 3D classification, 73,767 good particles were selected for  
141 further no-alignment 3D classification. Because of the relatively flexible organization between  
142 INTAC and PEC, the mask of INTS1-INTS6-INTS9-INTS11-PEC was applied to no-alignment  
143 3D classification to separate the weakly associated INTAC-PEC. Finally, 41,201 particles  
144 (stably associated INTAC-PEC) were subjected to 3D-autorefinement, postprocessing, CTF  
145 refinement and Bayesian polishing, yielding a reconstruction of INTAC-PEC at 4.18  $\text{\AA}$   
146 resolution. In order to improve the map quality for model building, focused classification and  
147 refinement were used. Afterwards, selected particles were postprocessed, CTF-refined,  
148 Bayesian polished and generated reconstructions of the INTAC at 3.72  $\text{\AA}$  (127,686 particles),  
149 INTS2-INTS7-CTD at 3.46  $\text{\AA}$  (127,686 particles), PP2A-AC at 3.81  $\text{\AA}$  (119,859 particles),  
150 INTS9-INTS11-Pol II-DSIF at 3.75  $\text{\AA}$  (67,991 particles), INTS9-INTS11-RNA at 3.80  $\text{\AA}$   
151 (67,991 particles) and INTS11-RNA at 3.66  $\text{\AA}$  (67,991 particles). The reported resolutions

152 above are based on the gold-standard Fourier shell correlation (FSC) 0.143 criterion. All the  
153 visualization and evaluation of 3D density maps were performed with UCSF Chimera  
154 ([Pettersen et al., 2004](#)) or UCSF ChimeraX ([Pettersen et al., 2021](#)), and the local resolution  
155 variations were calculated using ResMap. The above procedures of data processing are  
156 summarized in Fig.S2.

157

### 158 **Model building and structure refinement**

159 The structural model of INTAC-PEC was built according to the 4.18 Å INTAC-PEC cryo-  
160 EM map and corresponding focused refined maps. The structures of human INTAC (PDB:  
161 7CUN) and PEC (PDB: 6GML) were used to guide modeling of INTAC-PEC, which were  
162 docked into the INTAC-PEC cryo-EM map by rigid body fitting using UCSF Chimera  
163 ([Pettersen et al., 2004](#)) and were manually adjusted using COOT ([Emsley and Cowtan, 2004](#)).  
164 The models of INTS1, INTS2, INTS4, INTS8, INTS9 and INTS11 were further optimized in  
165 the guidance of the protein structures predicted by AlphaFold ([Jumper et al., 2021](#)). To build  
166 the model of INTS11 (active conformation) and RNA (-20 to -23), the homologous structure of  
167 CPSF with nascent RNA (PDB: 6V4X) was used as a reference according to the INTS9-  
168 INTS11-RNA map and the model of RNA (-1 to -10) was built using map INTS11-RNA.

169 The structural model of the INTAC-PEC complex was refined against the 4.18 Å overall  
170 map in real space with PHENIX ([Adams et al., 2002](#)) and validated through examination of  
171 Ramachandran plot statistics, a MolProbity score ([Chen et al., 2010](#)), and a EMRinger score  
172 ([Barad et al., 2015](#)). The statistics of the map reconstruction and model refinement are  
173 summarized in Table 1. Each focused refined maps were used to create the composite map using  
174 UCSF ChimeraX ([Pettersen et al., 2021](#)). The composite map was used in Fig. 1A and Video  
175 S1. Map and model representations in the figures and videos were prepared by PyMOL and  
176 UCSF ChimeraX ([Pettersen et al., 2021](#)).

177

178 **REFERENCE:**

- 179 Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCoy, A.J., Moriarty, N.W.,  
180 Read, R.J., Sacchettini, J.C., Sauter, N.K., and Terwilliger, T.C. (2002). PHENIX: building  
181 new software for automated crystallographic structure determination. *Acta Crystallogr D*  
182 *Biol Crystallogr* 58, 1948-1954.
- 183 Barad, B.A., Echols, N., Wang, R.Y.-R., Cheng, Y., Dimaio, F., Adams, P.D., and Fraser, J.S.  
184 (2015). EMRinger: side chain-directed model and map validation for 3D cryo-electron  
185 microscopy. *Nature Methods* 12, 943-946.
- 186 Boreikaite, V., Elliott, T.S., Chin, J.W., and Passmore, L.A. (2022). RBBP6 activates the pre-  
187 mRNA 3' end processing machinery in humans. *Genes Dev* 36, 210-224.
- 188 Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J.,  
189 Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010). MolProbity: all-atom  
190 structure validation for macromolecular crystallography. *Acta Crystallogr D Biol*  
191 *Crystallogr* 66, 12-21.
- 192 Chen, X., Qi, Y., Wu, Z., Wang, X., Li, J., Zhao, D., Hou, H., Li, Y., Yu, Z., Liu, W., *et al.* (2021).  
193 Structural insights into preinitiation complex assembly on core promoters. *Science* 372,  
194 eaba8490.
- 195 Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta*  
196 *Crystallogr D Biol Crystallogr* 60, 2126-2132.
- 197 Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool,  
198 K., Bates, R., Žídek, A., Potapenko, A., *et al.* (2021). Highly accurate protein structure  
199 prediction with AlphaFold. *Nature* 596, 583-589.
- 200 Kastner, B., Fischer, N., Golas, M.M., Sander, B., Dube, P., Boehringer, D., Hartmuth, K.,  
201 Deckert, J., Hauer, F., Wolf, E., *et al.* (2008). GraFix: sample preparation for single-particle  
202 electron cryomicroscopy. *Nat Methods* 5, 53-55.
- 203 Mastronarde, D.N. (2005). Automated electron microscope tomography using robust prediction  
204 of specimen movements. *J Struct Biol* 152, 36-51.
- 205 Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and  
206 Ferrin, T.E. (2004). UCSF Chimera--a visualization system for exploratory research and  
207 analysis. *J Comput Chem* 25, 1605-1612.
- 208 Pettersen, E.F., Goddard, T.D., Huang, C.C., Meng, E.C., Couch, G.S., Croll, T.I., Morris, J.H.,  
209 and Ferrin, T.E. (2021). UCSF ChimeraX: Structure visualization for researchers,  
210 educators, and developers. *Protein Sci* 30, 70-82.
- 211 Punjani, A., Rubinstein, J.L., Fleet, D.J., and Brubaker, M.A. (2017). cryoSPARC: algorithms  
212 for rapid unsupervised cryo-EM structure determination. *Nat Methods* 14, 290-296.
- 213 Scheres, S.H. (2012). RELION: implementation of a Bayesian approach to cryo-EM structure  
214 determination. *J Struct Biol* 180, 519-530.
- 215 Sun, Y., Zhang, Y., Aik, W.S., Yang, X.C., Marzluff, W.F., Walz, T., Dominski, Z., and Tong, L.  
216 (2020). Structure of an active human histone pre-mRNA 3'-end processing machinery.  
217 *Science* 367, 700-703.
- 218 Vos, S.M., Farnung, L., Boehning, M., Wigge, C., Linden, A., Urlaub, H., and Cramer, P.  
219 (2018a). Structure of activated transcription complex Pol II-DSIF-PAF-SPT6. *Nature* 560,

220 607-612.

221 Vos, S.M., Farnung, L., Urlaub, H., and Cramer, P. (2018b). Structure of paused transcription  
222 complex Pol II-DSIF-NELF. *Nature* 560, 601-606.


223 Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J.W., Strack, S., Jeffrey, P.D., and Shi,  
224 Y. (2006). Structure of the protein phosphatase 2A holoenzyme. *Cell* 127, 1239-1251.

225 Zheng, H., Qi, Y., Hu, S., Cao, X., Xu, C., Yin, Z., Chen, X., Li, Y., Liu, W., Li, J., *et al.* (2020).  
226 Identification of Integrator-PP2A complex (INTAC), an RNA polymerase II phosphatase.  
227 *Science* 370, eabb5872.

228 Zheng, S.Q., Palovcak, E., Armache, J.P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017).  
229 MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron  
230 microscopy. *Nat Methods* 14, 331-332.

231

232



233

234

**Supplementary Figure 1. Protein purification and complex assembly.**

235

used in biochemical and structural analyses. The samples were subjected to SDS-PAGE and

236

stained using Coomassie blue. Pol II represents RNA polymerase II purified from *S. scrofa* and

237

hPol II represents the Pol II overexpressed and purified from Expi293F cells. hPol II $\Delta$ CTD

238

represents hPol II containing truncation of RPB1 CTD (residues 1593-1970). To better reveal

239

phosphorylated hPol II and CTD truncation of RPB1, the lower bands of Pol II subunits were

240

omitted. (B) Glycerol density gradient of the mixture of INTAC and PEC. Peak fractions of the

241



assembled INTAC-PEC complex are indicated with red stars below. (C and D) IgG pulldown

242


assay using protein A (ProA)-tagged CTD (C) and DSIF and NELF (D) to test their binding of

243


INTAC. Contaminating proteins (Hsp70 and Tubulin) are indicated with black stars.



244  
 245 **Supplementary Figure 2. Data processing.** (A) Flow-charts of the cryo-EM image processing  
 246 and 3D reconstructions. (B and C) Representative cryo-EM raw micrograph (B) and 2D  
 247 classification (C) of INTAC-PEC. (D - J), The GSFSC curves, angular distribution plots, and  
 248 local resolution estimation of the cryo-EM maps of global refinement (D) and focused  
 249 refinements (E - J).




250  
 251 **Supplementary Figure 3. Cryo-EM maps and structural models.** (A) Composite cryo-EM  
 252 map of INTAC-PEC as shown in Fig. 1A. The positions of each submodule shown in (B) - (G)  
 253 are indicated on the overall map. (B - G) Cryo-EM density for each submodule, and close-up  
 254 views of representative structural models with the corresponding cryo-EM maps shown in  
 255 surface. Proteins are shown in ribbon and sticks (side chains). Most of the side chains fit into  
 256 the cryo-EM map, indicating the model was built correctly.



257  
 258  
 259  
 260  
 261  
 262  
 263


**Supplementary Figure 4. Conformational changes of INTAC and PEC upon formation of INTAC-PEC.** Structural comparisons of INTAC-PEC with INTAC (PDB: 7CUN) ([Zheng et al., 2020](#)) (A) and PEC (PDB: 6GML) ([Vos et al., 2018b](#)) (B). For clarity, INTAC-PEC is colored in grey and other complexes are colored as indicated. Structural differences are highlighted and modular displacements are indicated with arrows. Two different views are shown for each comparison.




264

265 **Supplementary Figure 5. Interfaces between INTAC and PEC.** (A) Overall structure of  
 266 INTAC-PEC with the five inter-complex contacts highlighted. (B - F) Interface-I to -V are  
 267 shown with structural models (right or bottom panels) and structural models covered by  
 268 transparent cryo-EM maps (left or upper panels) as shown in Fig. 1C - G. The two panels are

269 shown in similar orientation. Contacts are highlighted with dashed circles. Interactions between  
270 INTAC and Pol II CTD are omitted here and shown in Fig. S6.



271  
 272 **Supplementary Figure 6. Binding of Pol II CTD to INTAC backbone and PP2A-C.** (A –  
 273 D) Interactions between INTAC and four CTD segments. Electrostatic potential surface of  
 274 INTAC is shown. CTD2 and CTD3 are shown in sticks with heptad peptide indicated. As shown  
 275 in Fig. 2A, the cryo-EM maps did not support unambiguous assignment of CTD1 and CTD4.  
 276 The two segments are shown in cartoon. R1, R2 and R3 represent the repeat number of heptad  
 277 peptide. (E and F) Cryo-EM maps around CTD2 and CTD3 segments. Cryo-EM maps are  
 278 shown in purple meshes. Residues that potentially involved in recognition of CTD are shown  
 279 in sticks. (G) Comparison of CTD4 and MC-LR (PP2A inhibitor) in INTAC-PEC and PP2A  
 280 holoenzyme (Xu et al., 2006) structures. The two PP2A-C structures are shown in a similar  
 281 orientation.



282

283 **Supplementary Figure 7. Binding of RNA within the RNA entry tunnel of INTS11.** (A)

284 Contacts between PEC and endonuclease module of INTAC. (B) Cryo-EM map of the RNA

285 within INTS11 is shown in mesh and the RNA is shown in sticks. (C) Structural comparison of

286 the RNA-bound INTS11 in INTAC-PEC and the RNA-bound CPSF73 in HCC (PDB: 6V4X)

287 ([Sun et al., 2020](#)). Note that RNA was not cleaved in HCC complex. (D) The partial RNA

288 cleavage assay of INTAC (WT) and INTAC (E203Q) using a 40-nt RNA as a substrate. INTAC

289 (WT): wild type INTAC, INTAC (E203Q): INTAC with INTS11-E203Q mutation. Note that

290 only FAM-labeled 5' end-containing products could be visualized. Representative RNA

291 cleavage products are highlighted in red stars. The purified INTAC (WT) and INTAC (E203Q)

292 were subjected to SDS-PAGE. (E) The patrial RNA cleavage assay of INTAC (WT) using a  
293 different RNA substrate (40-nt\*). Representative RNA cleavage products are highlighted in red  
294 stars.

295

**Table S1. Cryo-EM data collection, refinement and validation statistics**

	#1 INTAC-PEC (EMDB-33741) (PDB 7YCX)	#2 INTS2-INTS7-CTD	#3 INTS9-INTS11-RNA
<b>Data collection and processing</b>			
Magnification	130,000x	130,000x	130,000x
Voltage (kV)	300	300	300
Electron exposure (e-/Å <sup>2</sup> )	50	50	50
Defocus range (µm)	-1.5 to -2.5	-1.5 to -2.5	-1.5 to -2.5
Pixel size (Å)	1.054	1.054	1.054
Symmetry imposed	C1	C1	C1
Initial particle images (no.)	1,795,128	1,795,128	1,795,128
Final particle images (no.)	41,201	127,686	67,991
Map resolution (Å)	4.2	3.5	3.8
FSC threshold	0.143	0.143	0.143
Map resolution range (Å)	4.0-10.0	3.4-5.4	3.7-9.0
<b>Refinement</b>			
Initial model used (PDB code)	7CUN, 6GML		
Model resolution (Å)	4.2		
FSC threshold	0.5		
Map sharpening <i>B</i> factor (Å <sup>2</sup> )	-90	-92	-105
Model composition			
Non-hydrogen atoms	113, 172		
Protein residues	14, 739		
Nucleotide residues	104		
Ligands	MN: 2, MG: 1, ZN: 10		
<i>B</i> factors (Å <sup>2</sup> )			
Protein	96.68		
Nucleotide	229.88		
Ligand	157.45		
R.m.s. deviations			
Bond lengths (Å)	0.004		
Bond angles (°)	0.632		
Validation			
MolProbity score	1.96		
Clashscore	11.34		
Poor rotamers (%)	0.17		
Ramachandran plot			
Favored (%)	94.32		
Allowed (%)	5.54		
Disallowed (%)	0.14		

298 **Supplementary Video 1**

299 Composite cryo-EM map and structural model of INTAC-PEC.

300 **Supplementary Video 2**

301 The CTD-binding path on INTAC. Cryo-EM map and structural model of CTD-binding path  
302 and four putative CTD fragments are shown. Pol II is shown to indicate its relative position to  
303 the CTD-binding path. The last modeled residue of RPB1 (P1487) is indicated with red ball.

304 **Supplementary Video 3**

305 Cryo-EM map and structural model of PEC and endonuclease module of INTAC. The RNA is  
306 colored in yellow.

307 **Supplementary Video 4**

308 Binding of RNA-bound PEC to INTAC leads to activation of INTS11. Non-related modules  
309 were omitted for simplicity.